Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

Investment Resolutions for the New Year

Risk mitigation and sector diversification are two areas where I look to improve in 2022.

2 Battered Biotech Stocks That Insiders Are Buying

Often this can signal a potential substantial turnaround in the shares.

Caution Signs Are Flashing in My Mind as the New Year Begins

The biotech sector looks ripe for staging a comeback, but a significant geopolitical event could throw the entire market for a loop.

Options Play of the Week: Take a Chance on This Small Biopharma in 2022

After a huge drop in recent weeks, these shares look oversold -- and an insider seems to agree.

Will These 2 Beaten Down Names Be Prosperous in the New Year?

Katapult and Incyte may have brighter days ahead.

2 Stocks Benefiting From the Great American Migration

The pandemic and government actions taken because of it have brought about significant and permanent changes to the country.

BioDelivery Sciences Is My Stock Pick for 2022

A successful launch of ELYXYB, solid revenue growth and increasing cash flow seems on the horizon.

Options Play of the Week: It's All Happening at the 'Zoo'

Our covered call idea for Monday should benefit from two trends we're seeing as we close out the year.

These 2 Undervalued Biotechs Are Ripe for Acquisition

Mirum Pharmaceuticals and TG Therapeutics are undervalued as stand-alone entities, but also would make easy and logical targets for a larger player.

I'm Cautious About Economic Growth Forecasts in 2022

It looks like gridlock is now the baseline scenario investors need to price into their portfolios.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight